Effect of Concomitant Oral Administration of Some Adsorbing Drugs on the Bioavailability of Metronidazole

Molokhia, Abdulla M.; Al-Rahman, Sherif H. Abd

doi:10.3109/03639048709116231

Cited by 5 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 Adsorbing drugs included an antidiarrheal mixture (kaolin and pectin), an antacid mixture (aluminum hydroxide and simethicone), and cholestyramine. The antidiarrheal mixture was found to affect the BA of metronidazole insignificantly; however, its BA was significantly reduced with the antacid mixture and with the anion exchange resin cholestyramine.…”

Section: Pharmacokinetic Properties Absorption and Bioavailabilitymentioning

confidence: 99%

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metronidazole

Rediguieri¹,

Porta

Nunes³

et al. 2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Pharmacokinetic Properties Absorption and Bioavailabilitymentioning

confidence: 99%

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metronidazole

Rediguieri¹,

Porta

Nunes³

et al. 2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…In vitro studies have failed to show an interaction, but other studies have demonstrated an approximate 20% reduction in metronidazole bioavailability. 49 Without conclusive data, the administration of ion-binding resins and metronidazole should be separated by at least 2 h. 50 Despite binding of vancomycin and potentially metronidazole, ion-exchange resins have a mild adverse effect potential and are inexpensive, making them attractive adjunctive treatment options to standard therapy for CDI. Current suggestions for the use of ionexchange resins include colestipol 5 g every 12 h or cholestyramine 4 g three to four times daily for 1 to 2 weeks, in conjunction with metronidazole or vancomycin, administered at least 2 h after the oral antibiotic dose.…”

Section: Ion-exchange Resinsmentioning

confidence: 99%

Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection

Musgrave

Bookstaver

Sutton

et al. 2011

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Infection with Clostridium difficile is currently the leading cause of infectious diarrhea in hospitalized patients, and recent surveillance data indicate that C. difficile has surpassed methicillin-resistant Staphylococcus aureus as the number one cause of hospital-acquired infections in some areas of the USA. In addition, concern over C. difficile has increased over the past decade due to the appearance of new hypervirulent strains. Metronidazole and vancomycin have remained the treatments of choice for initial therapy of primary infection with C. difficile for the past 25 years, but the persistence of spores leads to a recurrence of infection in an estimated 20-25% of patients. Patients who have one recurrent episode have up to a 65% chance of having additional recurrence. While the judicious use of antimicrobials in accordance with antibiotic stewardship guidelines remains the most effective method for the control of C. difficile, the high recurrence rate, increasing incidence, and changing epidemiology of C. difficile has led to an increased interest in the study of alternative strategies for the prevention and treatment of C. difficile disease. These alternative strategies attempt to eliminate C. difficile spores, replenish the normal gut flora, reduce the C. difficile toxin load in the bowel, or bolster the patient's own immune response to the C. difficile toxins. To evaluate the available evidence on these alternative strategies, we conducted a literature search of MEDLINE (1966-March 2011) and International Pharmaceutical Abstracts (1970-March 2011). Available citations from these articles were also utilized. The aim of this review is to summarize the available evidence for alternative treatment strategies for C. difficile disease and to make recommendations for their place in therapy.

show abstract

Interruption of the enterohepatic circulation of indomethacin by cholestyramine in rabbits

Al‐Meshal

El–Sayed

Al‐Angary

et al. 1990

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Effect of Concomitant Oral Administration of Some Adsorbing Drugs on the Bioavailability of Metronidazole

Cited by 5 publications

References 7 publications

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metronidazole

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Metronidazole

Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection

Interruption of the enterohepatic circulation of indomethacin by cholestyramine in rabbits

Contact Info

Product

Resources

About